<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01885832</url>
  </required_header>
  <id_info>
    <org_study_id>TBS-SVF-OA-002-2013</org_study_id>
    <nct_id>NCT01885832</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility Study of Autologous Stromal Vascular Fraction (SVF) Cells for Treatment of Osteoarthritis</brief_title>
  <official_title>Safety and Feasibility Study of Autologous Stromal Vascular Fraction (SVF) Cells for Treatment of Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autologous stromal vascular fraction (SVF) injected into joints of 20 patients with grade 2,&#xD;
      3, or 4 radiographic OA severity will be safe and feasible as assessed by lack of treatment&#xD;
      associated adverse events. Improvements in joint function as assessed by Western Ontario and&#xD;
      McMaster Universities Osteoarthritis Index (WOMAC) are anticipated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a single center, unblinded, non randomized, phase I/II trial in which&#xD;
      the patients will be treated with a single dose of autologous stromal vascular cells (SVF)&#xD;
      isolated from 500 ml of adipose tissue extracted from the infraumbilical area. The cellular&#xD;
      product will be administered via intra-articular injection into patients with moderate to&#xD;
      severe osteoarthritis (OA). Administration will be performed by injection into the synovial&#xD;
      space. The dosing regimen will consist of two intraarticular injection of autologous SVF into&#xD;
      the index knee. Total injection volume will be about 30 mL in two 15 mL aliquots via a 23&#xD;
      gauge needle inserted 1.5 cm. deep into the intraauricular space of the knee. The total&#xD;
      number of SVF to be injected is 1.0 x 10(7) to 5 x 10(7).&#xD;
&#xD;
      The purpose of this study will be to define the safety and efficacy of SVF therapy in&#xD;
      improving joint function and the quality of life in patients with OA of the knee. We plan to&#xD;
      enroll twenty subjects for treatment for an adequate sample size for safety analysis with&#xD;
      signals of efficacy. The primary safety outcome will be tabulation of adverse events related&#xD;
      to treatment. Efficacy will be quantified at 3, 6 and 12 months by the total Western Ontario&#xD;
      and McMaster Universities Osteoarthritis Index (WOMAC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    per sponsor decision&#xD;
  </why_stopped>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Kellgren-Lawrence classification at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline WOMAC Assessment at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the treatment arm, autologous stromal vascular fraction (SVF) will be injected into joints of 20 patients with grade 2, 3, or 4 radiographic OA severity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous adipose tissue stromal vascular fraction</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age &gt;18 years and ability to understand the planned treatment.&#xD;
&#xD;
        Idiopathic or secondary osteoarthritis of the knee with grade 2, 3, or 4 radiographic&#xD;
        severity, as defined by the modified Kellgren-Lawrence classification&#xD;
&#xD;
        Ability and willingness to undergo liposuction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pregnant women or cognitively impaired adults.&#xD;
&#xD;
        Presence of large meniscal tears (&quot;bucket handle&quot; tears), as detected by clinical&#xD;
        examination or by magnetic resonance imaging.&#xD;
&#xD;
        Inflammatory or postinfectious arthritis.&#xD;
&#xD;
        More than 5 degrees of varus or valgus deformity.&#xD;
&#xD;
        Kellgren Lawrence grade 4 osteoarthritis in two compartments (the medial or lateral&#xD;
        compartments of the tibiofemoral joint or the patellofemoral compartment) in persons over&#xD;
        60 years of age.&#xD;
&#xD;
        Intraarticular corticosteroid injection within the previous 3 months.&#xD;
&#xD;
        A major neurologic deficit.&#xD;
&#xD;
        Serious medical illness with a life expectancy of less than 1 year.&#xD;
&#xD;
        Prior admission for substance abuse&#xD;
&#xD;
        Body Mass Index (BMI) of 40 kg/m2 or greater&#xD;
&#xD;
        Patient receiving experimental medication or participating in another clinical study within&#xD;
        30 days of signing the informed consent&#xD;
&#xD;
        In the opinion of the investigator or the sponsor the patient is unsuitable for cellular&#xD;
        therapy&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Paz-Rodriguez, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stem Cell Institute Panama</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stem Cell Instsitute</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Panama</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>June 18, 2013</study_first_submitted>
  <study_first_submitted_qc>June 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2013</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autologous adipose stem cells</keyword>
  <keyword>stromal vascular fraction</keyword>
  <keyword>osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

